NEW YORK (GenomeWeb News) – Cellular Dynamics today said that it has licensed exclusive rights to a patent portfolio covering the optimization of the stem cell differentiation selection process and the use of heart cells in drug testing.
The Madison, Wis.-based firm said that it obtained the license from Loren Field and Indiana University-Purdue University Indianapolis (IUPUI). It covers two concepts for using stem cell-derived cells for drug screening: a cell purification strategy that enables greater than 90 percent purity of any type of cells, and the use of stem cell-derived cardiomyocytes for drug testing.
Financial terms of the deal were not disclosed.
Cellular Dynamics said that it will use the Field technology in conjunction with the patents it has licensed from the Wisconsin Alumni Research Foundation to "create a pipeline that mass produces cells for large-scale drug screening campaigns at pharmaceutical companies and for regenerative medicine applications."